In particular, these MVPs generated in response to chemotherapy or targeted therapies carry a potent phospholipid mediator, platelet-activating factor-receptor (PAFR) agonist, which has been shown to be involved in augmenting lung cancer growth and metastasis in a PAFR-dependent manner [49]. Here, PTAFR is linked to lung cancer.